Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 98

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 98
---
 for significant
input in selecting and evaluating new products to pursue. These independent organizations, advisors and consultants may not continue to
be available to us on a timely basis when needed, and in such case, we may not have the ability to find qualified replacements. In addition,
if we are unable to effectively manage our outsourced activities, or if the quality or accuracy of the services provided by consultants
is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory
approval of our drug candidates or otherwise advance our business. Furthermore, we may not be able to manage our existing consultants
or find other competent outside contractors and consultants on economically reasonable terms, if at all.

<div align='center'>51</div>

If we are not able to effectively
expand our organization by hiring new employees, outsourcing works or expanding our groups of consultants and contractors, we may not
be able to successfully implement the tasks necessary to further develop and commercialize our drug and diagnostics technology candidates
and, accordingly, may not achieve our research, development and commercialization goals.

We intend to seek additional collaborations, strategic alliances or acquisitions or enter into royalty-seeking or sublicensing arrangements in the future, but we may not realize the benefits of these arrangements.

We intend to form or seek strategic
alliances, create joint ventures or collaborations, acquire complimentary products, IP rights, technology or businesses or enter into
additional licensing arrangements with unrelated parties that we determine may complement or augment our development and commercialization
efforts with respect to our drug and diagnostics technology candidates. Any of these relationships may require us to incur non-recurring
and other charges, increase our near and long-term expenditures, issue securities that dilute our existing shareholders, or disrupt our
management and business.

We will face significant competition
in seeking appropriate strategic partners and the negotiation process is likely to be time-consuming, costly and complex. Moreover, we
may not be successful in our efforts to establish a strategic partnership or another alternative arrangement for any of our drug and diagnostics
technology candidates because their state of development may be deemed to be too early for collaborative effort and others may not view
our drug candidates as having the requisite potential to demonstrate safety and efficacy. If and when we enter into an agreement with
a collaboration partner or sublicensee for development and commercialization of a drug or diagnostics technology candidate, we can expect
to relinquish some or all of the control over the future success of that drug candidate to the unrelated-party.

Further,